Triglav Skladi D.O.O. Acquires New Shares in Gilead Sciences, Inc. (NASDAQ:GILD)

Triglav Skladi D.O.O. acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 16,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,478,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. HHM Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership bought a new position in Gilead Sciences in the 4th quarter worth about $28,000. Crews Bank & Trust bought a new position in Gilead Sciences in the 4th quarter worth about $31,000. Stephens Consulting LLC increased its stake in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 260 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC increased its stake in Gilead Sciences by 158.8% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 216 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the transaction, the chief financial officer now owns 165,674 shares of the company’s stock, valued at approximately $16,537,578.68. This represents a 1.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 25,429 shares of company stock valued at $2,894,445 in the last 90 days. Insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Morgan Stanley upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, April 25th. Bank of America upped their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Oppenheimer decreased their target price on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, April 25th. BMO Capital Markets upped their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Finally, Piper Sandler upped their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Gilead Sciences Trading Up 2.2%

GILD opened at $102.50 on Monday. The business has a 50 day simple moving average of $105.75 and a two-hundred day simple moving average of $99.84. The firm has a market capitalization of $127.50 billion, a price-to-earnings ratio of 277.03, a PEG ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Gilead Sciences’s quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.32) EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s payout ratio is 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.